



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/659,941	09/11/2003	Richard C. Potter	BASIC.034DV1C1	5072
20995	7590	02/09/2005	EXAMINER	
KNOBBE MARTENS OLSON & BEAR LLP			HENRY, MICHAEL C	
2040 MAIN STREET			ART UNIT	PAPER NUMBER
FOURTEENTH FLOOR				
IRVINE, CA 92614			1623	

DATE MAILED: 02/09/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/659,941	POTTER ET AL.	
	Examiner Michael C. Henry	Art Unit 1623	

— The MAILING DATE of this communication appears on the cover sheet with the correspondence address —

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on _____.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-52 is/are pending in the application.
 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
 5) Claim(s) ____ is/are allowed.
 6) Claim(s) 1-52 is/are rejected.
 7) Claim(s) ____ is/are objected to.
 8) Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date _____.
 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____.
 5) Notice of Informal Patent Application (PTO-152)
 6) Other: _____.

DETAILED ACTION

The following office action is a responsive to the Amendment filed, 10/18/04.

The amendment filed 10/18/04 affects the application, 10/659,941 as follows:

1. Claims 1, 2, 11, 12, 22, 23, 32, 33, 42, and 43 have been amended. This leaves claims 1-52.
2. Applicant responds to the rejection under 35 USC 112, 102 and 103 by amending said claims.

The responsive to applicants' arguments is contained herein below.

Claims 1-52 are pending in application

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 49 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 49 recite the limitation “said food product” in line 2. However, there is insufficient antecedent basis for this limitation in the claim. More specifically, there is no previous reference to the term “ food product” in the claim or in a claim from which claim 49 depends.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1,3-11,13-22, 24-32, 34-42, 44-50 are rejected under 35 U.S.C. 102(b) as being anticipated by Klein (US 5,980,918).

Claim 1 is a product-by-process claim wherein the applicant claims “A physiologically acceptable concentrated beta-glucan composition comprising a glucan having a mixed $\beta(1,3)(1,4)$ linked glucopyranosyl backbone prepared in an alcohol free process in the absence of organic solvents, wherein said beta-glucan composition has a concentration greater than 7% by weight.” Klein discloses applicant’s beta-glucan composition comprising a glucan having a mixed $\beta(1,3)(1,4)$ linked glucopyranosyl backbone, wherein said beta-glucan composition has a concentration 7-10% by weight (see col. 3, lines 18 to col. 4, line 9, and abstract). A quotation from the MPEP (Manual of Patent Examining Procedure, 8 ed., August 2001) pertaining to Product-by-Process Claims is given below in order for further corroborate the reason for the aforementioned rejection. The quotation states that “ PRODUCT-BY-PROCESS CLAIMS ARE NOT LIMITED TO THE MANIPULATIONS OF THE RECITED STEPS, ONLY THE STRUCTURE IMPLIED BY THE STEPS “[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process.” In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985).” Claims 3-8 which drawn to beta-glucan of claim 1 are also product-by-process claims which are rejected as being anticipated by Klein. Claim 9 which

is drawn to the composition of claim 1, wherein said beta- glucan is selected from those obtainable from oats, barley, is rejected by as being anticipated by Klein. It should be noted that the source from which the beta-gluican is obtained does not add to the patentability of the composition. Moreover, the source from which the said beta-glucan is obtained does not limit the claimed composition. It should also be noted that Klein's composition comes from oats (i.e., a milled bran fraction of oats) (see col. 3, lines 23-28 and abstract). Claim 10 which is drawn to the composition of claim 1, wherein said glucan is formulated for oral administration is also rejected by Klein, since applicant's claimed composition does not disclose any ingredient or substance that renders it different from Klein's composition or unsuitable for oral administration. In fact, Klein's composition comes from oats which is edible (i.e., a milled bran fraction of oats) (see col. 3, lines 23-28, and abstract). Claims 11,13-19, which are drawn to a dietary supplement for reducing low density lipoprotein and total serum cholesterol comprising concentrated beta-glucan are product by process claims which are anticipated by Klein, since applicant's claimed dietary supplement composition does not recite any ingredient or substance that renders it different from Klein's composition. It should be noted that the source from which the beta-glucan is obtained does not add to the patentability of the composition. Claim 20 which is drawn to the composition of claim 11, wherein said beta- glucan is selected from those obtainable from oats, barley, is rejected by as being anticipated by Klein. It should be noted that the source from which the beta-glucan is obtained does not add to the patentability of the composition. Moreover, the source from which the said beta-glucan is obtained does not limit the claimed composition. It should also be noted that Klein's composition comes from oats (i.e., a milled bran fraction of oats) (see col. 3, lines 23-28, and abstract). Claim 21 which is drawn to

the supplement of claim 11, wherein said beta glucan is formulated for oral administration, is rejected as being anticipated by Klein, since applicant's claimed composition does not disclose any ingredient or substance that renders it different from Klein's composition and suitable for oral administration. In fact, Klein's composition comes from oats which is edible (i.e., a milled bran fraction of oats) (see col. 3, lines 23-28, and abstract).

Claims 22, 24-30 which are drawn to a composition comprising concentrated (1,3)(1,4) beta glucan in a cosmetic composition are product by process claims which are anticipated by Klein, since Klein discloses applicant's cosmetic composition (a cream) containing cereal-derived beta-glucan (see col. 4, lines 53-65 and the abstract). It should be noted that the source from which the beta-glucan is obtained does not add to the patentability of the composition. Claim 31 which is drawn to the composition of claim 22, wherein said beta- glucan is selected from those obtainable from oats, barley , is rejected by as being anticipated by Misaki et al. It should be noted that the source from which the beta-glucan is obtained does not add to the patentability of the composition. Moreover, the source from which the said beta-glucan is obtained does not limit the claimed composition. In addition, Klein's composition comes from oats (i.e., a milled bran fraction of oats) (see col. 3, lines 23-28, and abstract).

Claims 32, 34-40 which are drawn to a composition comprising concentrated (1,3)(1,4) beta glucan in combination with a food product are product-by-process claims which are anticipated by Klein, since Klein's composition is also in combination with a food (oats) (see col. 3, lines 23-28, and abstract). Claim 41 which is drawn to the composition of claim 32, wherein said beta- glucan is selected from those obtainable from oats, barley , is rejected by as being anticipated by Klein. It should be noted that the source from which the beta-glucan

is obtained does not add to the patentability of the composition. Moreover, the source from which the said beta-glucan is obtained does not limit the claimed composition.

Claims 42, 44-50 which are drawn to a pharmaceutical composition comprising concentrated (1,3)(1,4) beta glucan and a pharmaceutically acceptable carrier are product-by-process claims which are anticipated by Klein, since Klein's composition also contain water which is a pharmaceutically acceptable carrier (see col.4, lines 52-65). It should be noted that the source from which the beta-glucan is obtained does not add to the patentability of the composition. Claim 51 which is drawn to the composition of claim 42, wherein said beta- glucan is selected from those obtainable from oats, barley is rejected by as being anticipated by Klein (see col.4, lines 52-65). It should be noted that the source from which the beta-glucan is obtained does not add to the patentability of the composition. Moreover, the source from which the said beta-glucan is obtained does not limit the claimed composition. Claim 52 which is drawn to the composition of claim 42, wherein said beta glucan is formulated for oral administration, is rejected as being anticipated by Klein, since applicant's claimed composition does not disclose any ingredient or substance that renders it different from Klein's composition or unsuitable for oral administration (see col.4, lines 52-65).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-50 are rejected under 35 U.S.C. 103(a) as being unpatentable over Klein (US 5,980,918).

Claim 1 is a product-by-process claim wherein the applicant claims "A physiologically acceptable concentrated beta-glucan composition comprising a glucan having a mixed $\beta(1,3)(1,4)$ linked glucopyranosyl backbone prepared in an alcohol free process in the absence of organic solvents, wherein said beta-glucan composition has a concentration greater than 7% by weight." In claim 2, applicant claims the composition of claim 1, wherein the concentration of the said beta glucan is greater than 68%. Dependent claims 12, 33 and 43 are drawn to compositions wherein the concentration of the said beta glucan is greater than 68%.

Klein discloses applicant's beta-glucan composition comprising a glucan having a mixed $\beta(1,3)(1,4)$ linked glucopyranosyl backbone, wherein said beta-glucan composition has a concentration 7-10% by weight (see col. 3, lines 18-29, and abstract).

The difference between applicant's claimed composition and the composition of Klein is the concentration in percent by weight of beta-glucan. However, Klein discloses that the beta-glucan can be used for healing burns and wounds and scarring (see abstract).

It would have been obvious to one having ordinary skill in the art, at the time the claimed invention was made to prepare Klein's beta glucan compositions comprising mixed (1,3)(1,4) linked glucopyranosyl backbone of different percent concentration to be used for healing burns, wounds and scars, based on factors like severity of burns, wounds or scars.

One having ordinary skill in the art would have been motivated, to prepare Klein's beta glucan compositions comprising mixed (1,3)(1,4) linked glucopyranosyl backbone of different

percent concentration to be used for healing burns, wounds and scars, based on factors like severity of burns, wounds or scars.

Response to Amendment

Applicant's arguments with respect to claims 1-52 have been considered but are moot in view of the new ground(s) of rejection.

The Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Henry whose telephone number is 571-272-0652. The examiner can normally be reached on 8:30 am to 5:00 pm; Mon-Fri. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be

Art Unit: 1623

reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308-1235.

MCH

January 28, 2005.



JAMES O. WILSON
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600